Cyprotex Final Results For The Year Ended 31 December 2008

Cyprotex (AIM:CRX), the drug discovery technology and information company, today reports its final results for the year ended 31 December 2008. Cyprotex enables its customers to access secure, high quality Absorption, Distribution, Metabolism, Excretion / Toxicity (ADMET) data without incurring significant overheads. Its highly automated platform guarantees high throughput, reproducibility and rapid turnaround of ADMET data, setting new industry standards for this sector of the market.

HIGHLIGHTS

• Revenues increased by 43% to £5.18 million (2007: £3.63 million)

• Gross profit rose by 49% to £4.48 million (2007: £3.00 million)

• Maiden operating profit of £567,000 (2007: loss of £496,000)

• Earnings per share of 0.36 pence (2007: loss per share of 0.35 pence)

• Successful fully subscribed Placing and Open Offer raised £1.00 million (£0.97 million net of costs) in August 2008

• Year end cash position improved significantly to £1.58 million notwithstanding continued investment (2007: £0.3 million)

Steve Harris, Chairman of Cyprotex, said:

“We are pleased to announce a significant increase in revenues and our maiden profit in 2008. Going forward we plan to expand the business both organically through strengthening relationships with our customers and selective collaborations, and through M&A activity.”